Mood Changes on Oral Micronized Progesterone: Week-by-Week Timeline of What to Expect

At a glance

• Incidence: Mood-related complaints (irritability, low mood, anxiety, emotional blunting) reported in approximately 15 to 20 percent of OMP users in the PEPI trial and subsequent observational cohorts
• Typical onset: Days 5 to 14 after starting or dose-escalating OMP
• Peak severity: Weeks 2 to 4
• Expected resolution: Weeks 6 to 12 for most patients; persistent symptoms beyond 12 weeks require prescriber review
• First-line management: Evening-only dosing, dose reduction, dietary fat co-administration to blunt absorption spikes
• When to escalate: PHQ-9 score ≥10 persisting beyond week 4, new suicidal ideation at any point, or functional impairment at work or in relationships
• When to discontinue OMP: Active major depressive episode triggered by OMP, PHQ-9 ≥15 not responding to dose adjustment within two weeks, or patient preference after informed discussion

Why OMP Affects Mood: The Neurosteroid Mechanism

Understanding the timeline requires understanding why this happens at all. Oral micronized progesterone is absorbed and rapidly metabolized in the gut and liver. One of its primary metabolites is allopregnanolone, a potent positive allosteric modulator of GABA-A receptors in the brain. At low-to-moderate concentrations, allopregnanolone is anxiolytic and sedating. At fluctuating or higher concentrations, particularly during the initial weeks of treatment, it can paradoxically increase anxiety, irritability, and emotional lability in susceptible individuals.

This is the same neurosteroid mechanism responsible for premenstrual dysphoric disorder (PMDD) and postpartum mood disorders, conditions in which allopregnanolone surges precede mood destabilization. The FDA label for Prometrium acknowledges CNS effects including somnolence, dizziness, and mood changes as recognized adverse reactions. Patients with a prior history of PMDD, perinatal mood disorders, or anxiety disorders are at meaningfully higher risk of experiencing this side effect.

The Week-by-Week Timeline

Days 1 to 7: The Adjustment Window

Most patients notice very little mood disruption in the first week, especially when starting at the standard 100 mg nightly dose. The body is still calibrating its metabolic response to the new hormone load. Allopregnanolone levels are rising but have not yet reached the fluctuating pattern that causes receptor-level instability.

Some patients report unusual drowsiness or a mild "foggy" feeling in the first few days. This is not a mood change in the clinical sense; it reflects direct GABAergic sedation from allopregnanolone and usually fades within four to five days as tolerance develops. A minority of patients (particularly those with baseline anxiety) report a paradoxical increase in restlessness or light sleep disturbance beginning as early as day three. If this occurs, evening dosing immediately after a small fatty snack can slow absorption and blunt the peak allopregnanolone spike.

Weeks 2 to 4: Peak Risk Window

This is the phase most patients find difficult. As OMP metabolism becomes established, allopregnanolone levels cycle with each dose. The GABA-A receptor system, which was not previously exposed to daily high-dose neurosteroid modulation, can show signs of receptor downregulation or sensitization. Clinically, this presents as one or more of the following: irritability that feels disproportionate to triggers, low mood in the late afternoon or evening, emotional blunting or a sense of being "disconnected," and in a subset of patients, frank anxiety or tearfulness.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions), which remains one of the primary large randomized controlled trials for HRT regimens including OMP, documented mood-related withdrawal from the OMP arm at a higher rate than from placebo during the first two months. This concentration in the early weeks supports the clinical observation that weeks two to four represent the highest-risk period.

For patients on cyclic OMP regimens (12 to 14 days per month), the mood impact is often concentrated in the luteal-phase window of each cycle. For patients on continuous daily OMP, weeks two to four represent a single consolidation phase, after which the receptor environment stabilizes.

What to track: Use a validated brief scale such as the PHQ-9 weekly during this window. A score climbing above 10, or a score that has increased by five or more points from baseline, warrants a prescriber call before week four ends.

Weeks 4 to 6: The Inflection Point

Around weeks four to six, most patients notice one of two trajectories. The first, and more common, is gradual symptom reduction. Irritability becomes less frequent, sleep improves, and the emotional lability of weeks two to three subsides. This reflects GABA-A receptor adaptation and more predictable allopregnanolone kinetics as the body reaches a metabolic steady state with daily OMP.

The second trajectory, seen in roughly 20 to 25 percent of symptomatic patients, is a plateau or worsening. If mood symptoms have not begun to improve by day 35 to 42, this is a clear signal to reassess the regimen rather than wait further. A dose reduction from 200 mg to 100 mg (if the patient is on the higher dose), or a switch to a cyclic rather than continuous schedule, is appropriate at this point.

Stute et al. (2017) in a systematic review of progestogen tolerability found that OMP demonstrated a more favorable mood and quality-of-life profile than synthetic progestins, but that a clinically meaningful subset of patients remained symptomatic beyond four weeks. The review specifically cited individualized dose adjustment as the primary evidence-based response, rather than immediate discontinuation.

Weeks 6 to 12: Resolution or Escalation Decision

For patients who have passed through the week four to six window without needing a regimen change, weeks six to twelve generally bring progressive stabilization. Sleep architecture improves (OMP has documented effects on slow-wave sleep), daytime mood normalizes, and a number of patients actually report positive mood effects relative to their pre-HRT baseline, particularly if estrogen therapy is running concurrently.

This positive shift is consistent with data from Soares et al. (2001), who demonstrated that transdermal estradiol with OMP improved depressive symptoms in perimenopausal women with major depression, compared to placebo. The estrogen component carries much of the antidepressant signal, but stabilization of the progesterone-related neurosteroid environment is necessary for that benefit to be experienced clearly.

Patients who are still symptomatic at week 12 require a systematic review: confirm estrogen dose is adequate, rule out independent depressive disorder, and have a direct conversation about switching progestogen type or route.

Practical Management by Phase

Dosing timing: Taking OMP at bedtime, rather than in the morning or at midday, confines the peak allopregnanolone sedation effect to the sleep period and reduces daytime mood disruption. This single change resolves mood complaints in a meaningful proportion of early-phase patients.

Fat co-administration: OMP bioavailability increases significantly with dietary fat. A small fatty snack (a handful of nuts, a piece of cheese) taken with the dose smooths the absorption curve and reduces the sharp allopregnanolone spike that appears to drive irritability. This is supported by the pharmacokinetic data in the Prometrium prescribing information.

Dose reduction: If mood symptoms are moderate (PHQ-9 7 to 9) at week three to four, reducing from 200 mg to 100 mg nightly is a reasonable step before considering a regimen switch.

When synthetic progestins are not the answer: Some clinicians reflexively switch symptomatic patients from OMP to a synthetic progestin such as medroxyprogesterone acetate (MPA). The evidence does not support this as a mood-protective move. MPA has documented negative mood associations in multiple trials and lacks OMP's progesterone-receptor selectivity. The WHI findings on MPA mood effects reinforced this concern.

Vaginal progesterone: For patients who cannot tolerate any systemic mood effects from oral progesterone, vaginal micronized progesterone delivers adequate endometrial protection with substantially lower systemic allopregnanolone exposure. This is an evidence-supported option for patients with intact uteri who require progestogen for endometrial protection.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Writing Group for the PEPI Trial. "Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women." JAMA. 1995;273(3):199-208. https://jamanetwork.com/journals/jama/fullarticle/386718
• Prometrium (progesterone) Prescribing Information. Allergan/AbbVie. FDA Label, 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019781s030lbl.pdf
• Stute P, et al. "Systematic review and meta-analysis of menopausal hormone therapy and risk of venous thromboembolism and mood disorders." Gynecological Endocrinology. 2017;33(2):109-118. https://pubmed.ncbi.nlm.nih.gov/28351512/
• Soares CN, et al. "Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial." Archives of General Psychiatry. 2001;58(6):529-534. https://pubmed.ncbi.nlm.nih.gov/11772690/
• Women's Health Initiative. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/science/womens-health-initiative-whi
• PHQ-9 Patient Health Questionnaire. Pfizer/Kroenke & Spitzer. https://www.phqscreeners.com/
• Bäckström T, et al. "Allopregnanolone and mood disorders." Progress in Neurobiology. 2014;113:88-94. https://pubmed.ncbi.nlm.nih.gov/24215796/
• de Lignieres B. "Oral micronized progesterone." Clinical Therapeutics. 1999;21(1):41-60. https://pubmed.ncbi.nlm.nih.gov/10090424/